Agios Pharmaceuticals (NASDAQ:AGIO) Stock Rating Lowered by Wall Street Zen

Agios Pharmaceuticals (NASDAQ:AGIO) was downgraded by equities researchers at Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Saturday.

AGIO has been the subject of a number of other reports. Leerink Partners raised their price target on shares of Agios Pharmaceuticals from $34.00 to $40.00 and gave the stock an “outperform” rating in a research report on Friday, December 26th. The Goldman Sachs Group dropped their price objective on shares of Agios Pharmaceuticals from $40.00 to $25.00 and set a “neutral” rating on the stock in a report on Thursday, November 20th. Bank of America raised their target price on shares of Agios Pharmaceuticals from $32.00 to $34.00 and gave the stock a “buy” rating in a report on Wednesday, December 24th. HC Wainwright boosted their target price on shares of Agios Pharmaceuticals from $62.00 to $65.00 and gave the company a “buy” rating in a research report on Thursday, February 12th. Finally, Truist Financial upped their price target on shares of Agios Pharmaceuticals from $32.00 to $38.00 and gave the company a “buy” rating in a report on Wednesday, December 24th. Six equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $40.67.

Agios Pharmaceuticals Stock Up 0.9%

Agios Pharmaceuticals stock opened at $27.85 on Friday. Agios Pharmaceuticals has a 52 week low of $22.24 and a 52 week high of $46.00. The company has a market capitalization of $1.63 billion, a price-to-earnings ratio of -3.92 and a beta of 0.89. The stock has a 50-day moving average price of $28.14 and a 200 day moving average price of $32.85.

Insider Buying and Selling

In other news, insider Sarah Gheuens sold 2,932 shares of Agios Pharmaceuticals stock in a transaction that occurred on Tuesday, December 30th. The shares were sold at an average price of $27.09, for a total transaction of $79,427.88. Following the completion of the transaction, the insider directly owned 64,795 shares of the company’s stock, valued at $1,755,296.55. The trade was a 4.33% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Brian Goff sold 18,703 shares of the business’s stock in a transaction on Tuesday, December 30th. The shares were sold at an average price of $27.09, for a total transaction of $506,664.27. Following the completion of the transaction, the chief executive officer owned 136,583 shares of the company’s stock, valued at approximately $3,700,033.47. This represents a 12.04% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 36,262 shares of company stock valued at $984,237 in the last three months. 4.93% of the stock is currently owned by company insiders.

Institutional Trading of Agios Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Marshall Wace LLP boosted its stake in shares of Agios Pharmaceuticals by 31.4% during the 2nd quarter. Marshall Wace LLP now owns 684,669 shares of the biopharmaceutical company’s stock worth $22,772,000 after acquiring an additional 163,796 shares in the last quarter. Assenagon Asset Management S.A. purchased a new stake in shares of Agios Pharmaceuticals in the third quarter valued at approximately $2,696,000. Frazier Life Sciences Management L.P. increased its position in shares of Agios Pharmaceuticals by 19.6% in the second quarter. Frazier Life Sciences Management L.P. now owns 1,279,754 shares of the biopharmaceutical company’s stock valued at $42,565,000 after buying an additional 209,900 shares in the last quarter. Boothbay Fund Management LLC raised its stake in shares of Agios Pharmaceuticals by 71.1% during the 2nd quarter. Boothbay Fund Management LLC now owns 447,019 shares of the biopharmaceutical company’s stock worth $14,868,000 after buying an additional 185,798 shares during the period. Finally, Erste Asset Management GmbH raised its stake in shares of Agios Pharmaceuticals by 18.8% during the 3rd quarter. Erste Asset Management GmbH now owns 2,764,900 shares of the biopharmaceutical company’s stock worth $108,578,000 after buying an additional 438,411 shares during the period.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.